BEVERLY, Mass., April 18, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX, "the Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions including drug-resistant cancers, is pleased to announce that its CEO Leo Ehrlich has conducted an interview with Biotech Stock Trader, a news and information portal for investors in pharmaceutical and biotechnology firms.  The interview provides additional insight into Cellceutix, the future path of the Company, and its business model. The company's potential and developments are discussed as well as the Cellceutix pipeline, upcoming clinical trials, and the Company's potential revolutionary cancer medication breakthrough with Kevetrin™ to reactivate p53, the "Guardian Angel of the Human Genome."

The interview is available for viewing on the Cellceutix website at http://www.cellceutix.com/news/BiotechStockTrader.html and at http://biotechstocktrader.com/cellceutix-otcqb-ctix-management-outlines-enormous-potential-in-exclusive-interview-200/.

Cellceutix also is pleased to announce that they have added renowned patent attorney, Dr. Paul Ginsberg, to their Advisory Board.

Cellceutix CEO Leo Ehrlich commented, "We are excited that Dr. Ginsberg wanted to expand his relationship with Cellceutix. Dr. Ginsberg has already been of great help in the patent process of Kevetrin™ and we look forward to his knowledge and experience as we finalize the patent application for our autism drug.  Dr. Ginsberg, with his in depth understanding of pharmaceutical chemistry, is a perfect fit to join our other amazing scientific advisors who have been of such enormous help to our early and extraordinary scientific successes. "

Commenting on joining the Cellceutix Advisory Board, Dr. Ginsburg stated, "I have been working closely with Cellceutix and Dr. Menon for some time now and based on my past experience in the field, I see great potential in the Company.  I am both pleased and excited to join the exceptional Cellceutix team and look forward to what the future may hold with not only Kevetrin™, but KM-391 for autism and other drugs in the pipeline which I have gotten to know quite well."

About Dr. Ginsberg

Dr. Ginsburg received his Ph.D. in Chemistry from the City University of New York and his law degree from Columbia University where he was a Harlan Fiske Stone Scholar.  He was elected to Phi Beta Kappa at the City College of New York and to the scientific research honor society Sigma Xi at CUNY. 

Dr. Ginsburg has spent most of his career as corporate counsel representing large and small pharmaceutical, biotechnology, chemical and consumer products companies.  His last position was at Pfizer Inc., where he served as Head of the New York Patent Department which dealt with several blockbuster products, including Viagra and Chantix.  He represented Pfizer on the intellectual property committees of the National Association of Manufacturers, the Chemical Manufacturers Association and the Biotechnology Industry Organization. Dr. Ginsburg has lectured widely on pharmaceutical and biotechnology patent prosecution and licensing at the Practicing Law Institute and Columbia Law School . Prior to his twenty year career at Pfizer, Dr. Ginsburg was a senior attorney at Schering-Plough. He was subsequently recruited by Merck and then by the highly respected IP law firm, Fish & Neave.

Dr. Ginsburg is perhaps most well-known as the author of the patent covering Schering-Plough's hugely successful product Claritin. He also authored important patents covering Schering-Plough's highly successful alpha-interferon product.

Dr. Ginsburg has authored the patent application for Cellceutix anticancer product Kevetrin™, which has been filed in the United States and other countries and has advised Cellceutix on patent and licensing matters during the past few years.

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

SOURCE Cellceutix Corporation